Valacyclovir for the treatment of genital herpes

References

• Elion GB, Furman PA, Fufe JA et al. Selectivity of action of an anti-herpetic agent, 9-[2-hydroxyethoxymethyl]guanine. Proc. Natl Acad. Sci. USA74, 5716–5720 (1997).
   Google Scholar
• Hayden RG. Antimicrobial agents. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Hardman JG, Limbirdeds LE (Eds), McGraw-Hill, NY, USA, 1191–1223 (1996).
   Google Scholar
• Ormrod D, Scott LJ, Perry CM. Valacyclovir: a review of its long-term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs59, 839–863 (2000).
   PubMed Web of Science ®Google Scholar
• Beutner KR, Friedman DJ, Forszpaniak C et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother.39, 1546–1553 (1995).
   PubMed Web of Science ®Google Scholar
• Luber AD, Flaherty JF. Famciclovir for treatment of herpesvirus infections. Ann. Pharmacother.30, 978–985 (1996).
   PubMed Web of Science ®Google Scholar
• Valtrex® (valacyclovir hydrochloride) product information. GlaxoSmithKline, USA, October (2005).
   Google Scholar
• Fife KG, Crumpacker CS, Mertz GJ et al. Recurrence and resistance patterns of herpes simplex virus following cessation of at least 6 years of chronic suppression with acyclovir. J. Infect. Dis.169, 1338–1341 (1994).
   PubMed Web of Science ®Google Scholar
• Kriesel JD, Spruance SL, Prichard M et al. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J. Infect. Dis.192(1), 156–161 (2005).
   PubMed Web of Science ®Google Scholar
• Reyes M, Shaik NS, Graber JM et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch. Intern. Med.163(1), 76–80 (2003).
   PubMed Web of Science ®Google Scholar
• Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolite disposition of valacyclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother.39(12), 2759–2764 (1995).
   PubMed Web of Science ®Google Scholar
• Burpo RH. Antiviral agents in women’s health: pharmacotherapeutics of treating influenza and herpes. J. Midwifery Womens Health47(3), 182–189 (2002).
   PubMed Web of Science ®Google Scholar
• Fife KH, Barbarash RA, Rudolph T et al. Valacyclovir versus acyclovir in the treatment of first-episode genital herpes infection. Sex. Transm. Dis.24, 481–486 (1997).
   PubMed Web of Science ®Google Scholar
• Spruance SL, Tyring SK, Degregorio B et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch. Intern. Med.156, 1729–1735 (1996).
   PubMed Web of Science ®Google Scholar
• Tyring SK, Douglas JM, Corey L et al. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch. Dermatol.134, 185–191 (1998).
   PubMedGoogle Scholar
• Bodsworth NJ, Crooks RJ, Borelli S et al. Valaciclovir versus aciclovir in patient intiated treatment of recurrent genital herpes: a randomized, double-blind clinical trial. Genitourin. Med.73, 110–116 (1997).
   PubMedGoogle Scholar
• Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin. Infect. Dis.34, 958–962 (2002).
   PubMed Web of Science ®Google Scholar
• Wald A, Carrell D, Remington M et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin. Infect. Dis.34, 944–948 (2002).
   PubMed Web of Science ®Google Scholar
• Aoki FY, Tyring S, Diaz-Mitoma F et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis.42, 8–13 (2006).
   PubMed Web of Science ®Google Scholar
• Patel R, Bodsworth NJ, Woolley P et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo-controlled study of once-daily therapy. Genitourin. Med.73, 105–109 (1997).
   PubMedGoogle Scholar
• Reitano M, Trying S, Lang W et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J. Infect. Dis.178, 603–610 (1998).
   PubMed Web of Science ®Google Scholar
• Baker DA, Blythe JG, Miller JM. Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes. Obstet. Gynecol.94, 103–106 (1999).
   PubMed Web of Science ®Google Scholar
• Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex. Transm. Infect.75, 398–402 (1999).
   PubMed Web of Science ®Google Scholar
• Romanowski B, Marina RB, Roberts JN; The Valtrex HS230017 Study Group. Patients’ preference of valacyclovir once-daily supppressive therapy versus twice-daily episodic therapy for recurrent genital herpes. Sex. Transm. Dis.30(3), 226–231 (2003).
   PubMed Web of Science ®Google Scholar
• Conant MA, Schacker TW, Murphy RL et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int. J. STD AIDS13, 12–21 (2002).
   PubMed Web of Science ®Google Scholar
• Spruance SL, Jones TM, Blatter MM et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob. Agents Chemother.47(3), 1072–1080 (2003).
   PubMed Web of Science ®Google Scholar
• Jensen LA, Hoehns JD, Squires CL. Oral antivirals for the acute treatment of recurrent herpes labialis. Ann. Pharmacother.38(4), 705–709 (2004).
   Google Scholar
• Wald A, Zeh J, Selke S et al. Virological characteristics of subclinical and symptomatic genital herpes infections. N. Engl. J. Med.333(12), 770–775 (1995).
   Google Scholar
• Anderson BJ. The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. Clin. J. Sport Med.9(2), 86–90 (1999).
   PubMed Web of Science ®Google Scholar
• Grant DM, Mauskopf JA, Bell L, Austin R. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Pharmacotherapy17(2), 333–341 (1997).
   PubMed Web of Science ®Google Scholar
• Tyring SK, Beutner KR, Tucker BA et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch. Fam. Med.9, 863–869 (2000).
   PubMedGoogle Scholar
• Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years’ experience with acyclovir. J. Infect. Dis.186(Suppl. 1), S40–S46 (2002).
   PubMed Web of Science ®Google Scholar
• Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced HIV disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine76, 369–380 (1997).
   PubMed Web of Science ®Google Scholar
• Chulay JD, Bell AR. Long-term safety of valaciclovir for suppression of herpes simplex virus infection [abstract 105]. Clin. Infect. Dis.23, 879 (1996).
   Google Scholar
• Gupta R, Wald A, Krantz E et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J. Infect. Dis.190(8), 1374–1381 (2004).
   PubMed Web of Science ®Google Scholar
• Corey L, Wald A, Patel R et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med.350(1), 11–20 (2004).
   PubMed Web of Science ®Google Scholar
• Griffiths PD. Tomorrow’s challenges for herpesvirus management: potential applications of valacyclovir. J. Infect. Dis.186(Suppl. 1), S131–S137 (2002).
   Google Scholar
• Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med.340, 1462–1470 (1999).
   PubMed Web of Science ®Google Scholar
• Sund F, Wahlberg J, Eriksson BM. CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valacyclovir. J. Clin. Virol.23, 107–111 (2001).
   PubMed Web of Science ®Google Scholar
• Reischig T, Opatrny K Jr, Bouda M, Treska V, Jindra P, Svecova M. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transpl. Int.15, 615–622 (2002).
   PubMed Web of Science ®Google Scholar
• Fiddian P, Sabin CA, Griffiths PD. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J. Infect. Dis.186(Suppl. 1), S110–S115 (2002).
   PubMed Web of Science ®Google Scholar
• Egan JJ, Carroll KB, Yonan N et al. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J. Heart Lung Transplant.21, 460–466 (2002).
   PubMed Web of Science ®Google Scholar
• Malouf MA, Chhajed PN, Hopkins P et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J. Heart Lung Transplant.21, 547–554 (2002).
   PubMed Web of Science ®Google Scholar
• Beeson WH, Rachel JD. Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing. Dermatol. Surg.28, 331–336 (2002).
   PubMed Web of Science ®Google Scholar
• Bech E, Lycke J, Gadeberg P et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology58, 31–36 (2002).
   PubMed Web of Science ®Google Scholar
• Scott LL. Prevention of perinatal herpes: prophylactic antiviral therapy? Clin. Obstet. Gynecol.42(1), 134–148 (1999).
   PubMed Web of Science ®Google Scholar
• Kroon S, Whitley RJ. Management strategies in herpes: can we improve management of perinatal HSV infection? In: Management Strategies in Herpes. PPS Europe Ltd, Worthing, UK, 19–21 (1995).
   Google Scholar
• Scott LL, Sanchez PJ, Jackson GL et al. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet. Gynecol.87(1), 69–73 (1996).
   PubMed Web of Science ®Google Scholar
• Sheffield JS, Hollier LM, Hill JB et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet. Gynecol.102(6), 1396–1403 (2003).
   PubMed Web of Science ®Google Scholar
• Kimberlin DF, Weller S, Andrews WW et al. Valaciclovir pharmacokinetics in late pregnancy. Am. J. Obstet. Gynecol.178, S12 (1998).
   Google Scholar
• Andrews WW, Kimberlin DF, Whitle R et al. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am. J. Obstet. Gynecol.194(3), 774–781 (2006).
   PubMed Web of Science ®Google Scholar